Proposed outcome measures extracted from primary care computer records using an automated extraction at the end of the study period
| Patient outcome measures | Male (n=46) | Female (n=72) |
|---|---|---|
| Age (years) | 58 (9.0) | 56 (7.5) |
| Total cholesterol (mmol/L) | 5.8 (1.5) | 6.4 (1.4) |
| LDL cholesterol (mmol/L) | 3.6 (1.3) | 3.8 (1.5) |
| Number with latest TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L (%) | 12 (26) | 23 (32) |
| Number with repeat cholesterol test within 6 months after study start date (%) | 41 (89) | 60 (83) |
| Number of diagnosed with secondary cause* within 6 months after study start date (%) | 5 (11) | 5 (7) |
| Number with any family history of coronary heart disease assessed within 6 months after study start date (%) | 14 (30) | 31 (43) |
| Number with any complete family history† of coronary heart disease assessed within 6 months after study start date (%) | 1 (2) | 6 (8) |
| Number with TSH assessed within 6 months after study start date‡ (%) | 14 (30) | 17 (23) |
| Number with HbA1c assessed within 6 months after study start date§ (%) | 6 (13) | 17 (24) |
| Number with serum creatinine assessed within 6 months after study start date¶ (%) | 19 (41) | 29 (40) |
| Number with bilirubin, ALP or gamma GT assessed within 6 months after study start date** (%) | 19 (41) | 22 (31) |
| Number with arcus senilis or xanthalasma diagnosed within 6 months after study start date (%) | 0 (0) | 0 (0) |
| Number of prescribed any statins within 6 months after study start date (%) | 14 (30) | 13 (18) |
| Number of prescribed high-potency statins†† within 6 months after study start date (%) | 4 (9) | 2 (3) |
| Number of given dietary or weight management advice within 6 months after study start date (%) | 27 (59) | 33 (46) |
| Number of given smoking cessation advice within 6 months after study start date (%) | 19 (41) | 15 (21) |
Variables are means and SDs unless otherwise specified.
*Diabetes, hypothyroidism, chronic kidney disease, liver disease.
†Complete family history is defined when age, condition and degree of relation to patient is documented.
‡Proxy for secondary investigations for hypothyroidism.
§Proxy for secondary investigations for diabetes.
¶Proxy for secondary investigations for chronic kidney disease.
**Proxy for secondary investigations for liver disease.
††Simvastatin ≥80 mg/day, atorvastatin ≥20 mg/day, rosuvastatin ≥10 mg/day.
ALP, alkaline phosphatase; GT, glutamyl transpeptidase; LDL, low density lipoprotein; TC, total cholesterol; TSH, thyroid stimulating hormone.